Uridine triacetate

Uridine triacetate (INN),[1] formerly known as vistonuridine, is an orally active tri-acetylated prodrug of uridine[2] used:

• in the treatment of hereditary orotic aciduria (brand name Xuriden /ˈzʊərədɛn/ ZOOR-ə-den);[3]
• to treat patients following an overdose of chemotherapy drugs 5-fluorouracil (5-FU) or capecitabine regardless of the presence of symptoms, or who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration (brand name Vistogard).[4][5][6]

Uridine triacetate

Clinical data
Trade names	Vistogard, Xuriden
AHFS/Drugs.com	Monograph
MedlinePlus	a616020
License data	US DailyMed: Uridine%20triacetate
Pregnancy category	US: N (Not classified yet)
Routes of administration	Oral granules
ATC code	A16AX13 (WHO)
Legal status
Legal status	US: ℞-only
Pharmacokinetic data
Metabolism	Pyrimidine catabolic pathway
Onset of action	Tmax = 2–3 hours
Elimination half-life	2–2.5 hours
Excretion	Renal
Identifiers
IUPAC name [(2R,3R,4R,5R)-3,4-diacetyloxy-5-(2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate
CAS Number	4105-38-8
PubChem CID	20058
DrugBank	DB09144
ChemSpider	18897
UNII	2WP61F175M
KEGG	D09985
ChEBI	CHEBI:90914
ChEMBL	ChEMBL2107381
CompTox Dashboard (EPA)	DTXSID70951914 DTXSID40961409, DTXSID70951914
ECHA InfoCard	100.021.710
Chemical and physical data
Formula	C15H18N2O9
Molar mass	370.314 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CC(=O)OCC1C(C(C(O1)N2C=CC(=O)NC2=O)OC(=O)C)OC(=O)C
InChI InChI=1S/C15H18N2O9/c1-7(18)23-6-10-12(24-8(2)19)13(25-9(3)20)14(26-10)17-5-4-11(21)16-15(17)22/h4-5,10,12-14H,6H2,1-3H3,(H,16,21,22)/t10-,12-,13-,14-/m1/s1 Key:AUFUWRKPQLGTGF-FMKGYKFTSA-N

Uridine triacetate was developed, manufactured and distributed by Wellstat Therapeutics. It was granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA) and approved for use in the United States in 2015.[7][8][9]

References

1. "International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 65" (PDF). World Health Organization. p. 92. Retrieved 12 March 2017.
2. "Uridine triacetate — DrugBank Page". 12 March 2017.
3. "Xuriden (uridine triacetate) Oral Granules. Full Prescribing Information" (PDF). Wellstat Therapeutics Corporation. Gaithersburg, MD 20878. Retrieved 12 March 2017.
4. "Vistogard (uridine triacetate) Oral Granules. Full Prescribing Information" (PDF). Wellstat Therapeutics Corporation. Gaithersburg, MD 20878. Retrieved 12 March 2017.
5. "BTG Announces FDA Approval of Vistogard^® (Uridine Triacetate) as Antidote to Overdose and Early Onset, Severe, or Life-Threatening Toxicities from Chemotherapy Drugs 5-Fluorouracil (5-FU) or Capecitabine". BTG International Ltd. 11 December 2015. Retrieved 12 March 2017.
6. "Approved Drugs — Uridine Triacetate". U.S. Food and Drug Administration. Retrieved 12 March 2017.
7. "Xuriden (uridine triacetate) oral granules". U.S. Food and Drug Administration (FDA). 8 October 2015. Archived from the original on 8 December 2019. Retrieved 7 December 2019. This article incorporates text from this source, which is in the public domain.
8. "Drug Trials Snapshots: Xuriden". U.S. Food and Drug Administration (FDA). 4 September 2015. Archived from the original on 8 December 2019. Retrieved 8 December 2019. This article incorporates text from this source, which is in the public domain.
9. "Previous Cumulative CY CDER BT Approvals". U.S. Food and Drug Administration (FDA). Archived from the original on 8 December 2019. Retrieved 7 December 2019. This article incorporates text from this source, which is in the public domain.

External links

• "Uridine triacetate". Drug Information Portal. U.S. National Library of Medicine.